Redeye comments on Fantasma Games’ Q1 results, which came in line with our expectations.
Redeye comments on Freemelt’s Q1 results which came in better than expected due to good cost control...
Redeye sees a relatively uneventful report with some positive highlights with continued progress in ...
Sales SEK +0.7m and adj. EBIT +28% vs. ABGSCe Positive FCF due to reduction in receivables Restructu...
Redeye remains confident in the case despite a slow start into 2023 in terms of top-line growth.
Redeye initiates coverage of Magle Chemoswed, a hybrid medtech/biotech company with a diverse array ...
NoHo Partners reported a strong Q1 with EBIT of EUR 5.
Vow published its Q1 update on 9 May, posting a 14% beat to company-compiled consensus on the top li...
Report due on Thursday, 11 May Current OH costs too big for new, smaller operations Focus now is on ...
Strong NWT sales, cash flow lags earnings NWT boosted by customers building inventory Share is tradi...
Better Q1 EBIT margin on lower opex... ...but we cut '23e-'25e EBIT by 4-2% on lower sales ARPU shou...
2% PTP beat despite higher-than-expected restructuring costs Higher costs are of a one-off nature – ...
Tangiamo publicerade den 9 maj 2023 bolagets delårsrapport för det första kvartalet 2023.
ADDvise, som förvärvar bolag inom hälso- och sjukvård, har fått en flygande start på 2023.
Odramatiskt Q1 med organisk tillväxt i de flesta dotterbolag VO2 redovisar ett kvartal där inget var...
Redeye states its view of Bredband2’s Q1 2023 report, released earlier today.
Redeye comments on Optomed’s announcement regarding its new AI partnership with Thirona Retina.
Fortsatt utmanande marknad i Norden och aktien är pressad.
Q1 adj. EBITA 11.5m vs. ABGSCe 13.5 Strong operational development and outlook No material changes t...
Sales SEK 19.2m, -7% vs. ABGSCe SEK 20.6m EBITDA SEK -0.
